Antibody–drug conjugates in colorectal cancer: target biology, resistance, and the clinical-trial landscape
Abstract
Colorectal cancer (CRC) remains a leading cause of cancer morbidity and mortality, and outcomes in microsatellite-stable metastatic disease have improved only modestly despite optimised cytotoxic, anti-VEGF and anti-EGFR regimens. Antibody–drug conjugates (ADCs) link tumour-associated antigen targeting to intracellular delivery of potent payloads, but their place in CRC is still being defined. We outline core design principles (target/antibody, linker, payload) and summarise clinical experience with constructs of direct or indirect relevance to CRC (trastuzumab deruxtecan, sacituzumab govitecan, trastuzumab emtansine). We then map the global CRC ADC pipeline using Trialtrove Clinical Intelligence and major registries, identifying 214 phase I–III studies. Disease-specific development streams are reviewed, focusing on HER2-, CEACAM5-and TROP2-directed ADCs, combination approaches pairing HER2-directed ADCs with chemotherapy or anti-angiogenic therapy, and next-generation concepts including LGR5-axis targeting and EGFR-based conjugates for stem-like or chemoresistant disease. Finally, we discuss class-wide challenges—treatment-related toxicities, primary and acquired resistance, and the need for harmonised biomarker strategies—and highlight how nanotechnology-enabled delivery and AI-guided target/biomarker optimisation may support more precise deployment. Overall, ADCs are a rational but early-stage option for biomarker-selected CRC, with clear activity in subsets and open questions on dosing, sequencing, combinations and long-term safety.
Related
- Antibody–drug conjugates in solid tumors: current landscape, challenges, and future directions
- Application of antibody-drug conjugates in colorectal cancer
- The immunological landscape of antibody-drug conjugates: from target to payload biology
- Efficacy and safety of antibody-drug conjugates in advanced small cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials
- Molecular and immune-mediated resistance to antibody-drug conjugates in breast cancer
BibTeX
@article{chen2026antibodydrug,
title = {{Antibody–drug conjugates in colorectal cancer: target biology, resistance, and the clinical-trial landscape}},
author = {Chaofan Chen and Luming Guo and Xu Han and Tingting Deng},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.1967108},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1967108},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Antibody–drug conjugates in colorectal cancer: target biology, resistance, and the clinical-trial landscape
AU - Chaofan Chen
AU - Luming Guo
AU - Xu Han
AU - Tingting Deng
PY - 2026
DA - 2026/11/10
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1967108
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1967108
AB - Colorectal cancer (CRC) remains a leading cause of cancer morbidity and mortality, and outcomes in microsatellite-stable metastatic disease have improved only modestly despite optimised cytotoxic, anti-VEGF and anti-EGFR regimens. Antibody–drug conjugates (ADCs) link tumour-associated antigen targeting to intracellular delivery of potent payloads, but their place in CRC is still being defined. We outline core design principles (target/antibody, linker, payload) and summarise clinical experience with constructs of direct or indirect relevance to CRC (trastuzumab deruxtecan, sacituzumab govitecan, trastuzumab emtansine). We then map the global CRC ADC pipeline using Trialtrove Clinical Intelligence and major registries, identifying 214 phase I–III studies. Disease-specific development streams are reviewed, focusing on HER2-, CEACAM5-and TROP2-directed ADCs, combination approaches pairing HER2-directed ADCs with chemotherapy or anti-angiogenic therapy, and next-generation concepts including LGR5-axis targeting and EGFR-based conjugates for stem-like or chemoresistant disease. Finally, we discuss class-wide challenges—treatment-related toxicities, primary and acquired resistance, and the need for harmonised biomarker strategies—and highlight how nanotechnology-enabled delivery and AI-guided target/biomarker optimisation may support more precise deployment. Overall, ADCs are a rational but early-stage option for biomarker-selected CRC, with clear activity in subsets and open questions on dosing, sequencing, combinations and long-term safety.
SN - 1663-9812
ER -